Skip to main content

Table 1 Characteristics of PWUD with chronic hepatitis C and factors associated with DAA uptake, univariable and multivariable Cox regression (ANRS FANTASIO study; 22,615 patients)

From: Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)

Variables

N (%) or

Univariable analyses

Multivariable analysis

Mean (SD) at inclusion

HR [95% CI]

p-value

aHR [95% CI]

p-value

Sex

Male (ref.)

17,682 (78.2)

1

 

1

 

Female

4933 (21.8)

0.79 [0.72–0.86]

< 0.001

0.82 [0.75–0.90]

< 0.001

Age (per 1-year increase)

46.4 (7.3)

1.04 [1.03–1.05]

< 0.001

1.03 [1.03–1.04]

< 0.001

Receiving CMU-C

No (ref.)

16,119 (71.3)

1

 

1

 

Yes

6496 (28.7)

0.82 [0.76–0.88]

< 0.001

0.91 [0.84–0.98]

0.018

Liver disease severity

No cirrhosis and no liver cancer (ref.)

21,650 (95.7)

1

 

1

 

Cirrhosis without liver cancer

776 (3.4)

4.33 [3.83–4.90]

< 0.001

3.99 [3.50–4.54]

< 0.001

Liver cancer

189 (0.8)

3.78 [2.85–5.03]

< 0.001

3.04 [2.27–4.06]

< 0.001

Alcohol use disorder (AUD)

No AUD (ref.)

18,247 (80.7)

1

 

1

 

Untreated AUD

3445 (15.2)

1.06 [0.96–1.17]

0.224

0.92 [0.83–1.01]

0.090

Treated AUD

923 (4.1)

1.08 [0.91–1.27]

0.369

1.06 [0.89–1.26]

0.505

Adherence to OAT*

Less than 20% (ref.)

17,224 (76.2)

1

 

1

 

20% and more

5391 (23.8)

1.28 [1.19–1.38]

< 0.001

1.28 [1.18–1.38]

< 0.001

Adherence to OAT*

0% (ref.)

13,081 (57.8)

1

   

1–19%

4143 (18.3)

0.94 [0.86–1.03]

0.205

20–39%

2126 (9.4)

1.35 [1.21–1.51]

< 0.001

  

40–59%

1077 (4.8)

1.37 [1.19–1.57]

< 0.001

  

60% + 

2188 (9.7)

1.12 [0.99–1.26]

0.069

  
  1. aHR, Adjusted hazard ratio; CI, confidence interval; CMU-C, complementary universal health coverage status (Couverture Maladie Universelle – complémentaire); DAA, direct-acting antivirals; HR, hazard ratio; OAT, opioid agonist therapy; PWUD, people who use drugs; SD, standard deviation
  2. *Time-varying variable, the numbers and percentages are calculated during the first six months of follow-up